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Abstract
Background: Marek’s disease virus (MDV) is an oncogenic herpesvirus, which causes malignant lymphoma in
chickens. The Meq protein of MDV, which is expressed abundantly in MDV-infected cells and in Marek’s disease
(MD) tumor cells, functions as a transcriptional activator and has been proposed to play an important role in
oncogenic transformation. Preliminary studies demonstrated that Meq is able to bind p53 in vitro, as demonstrated
using a protein-binding assay. This observation prompted us to examine whether the interaction between Meq
and p53 occurs in cells, and to investigate the biological significance of this interaction.
Results: We confirmed first that Meq interacted directly with p53 using a yeast two-hybrid assay and an
immunoprecipitation assay, and we investigated the biological significance of this interaction subsequently.
Exogenous expression of Meq resulted in the inhibition of p53-mediated transcriptional activity and apoptosis, as
analyzed using a p53 luciferase reporter assay and a TUNEL assay. The inhibitory effect of Meq on transcriptional
activity mediated by p53 was dependent on the physical interaction between these two proteins, because a Meq
deletion mutant that lacked the p53-binding region lost the ability to inhibit p53-mediated transcriptional activity
and apoptosis. The Meq variants L-Meq and S-Meq, but not VS-Meq and ΔMeq, which were expressed in MD
tumor cells and MDV-infected cells, exerted an inhibitory effect on p53 transcriptional activity. In addition, ΔMeq
was found to act as a negative regulator of Meq.
Conclusions: The Meq oncoprotein interacts directly with p53 and inhibits p53-mediated transcriptional activity
and apoptosis. These findings provide valuable insight into the molecular basis for the function of Meq in MDV
oncogenesis.
Background
Marek’s disease (MD), which is caused by Marek’sd i s -
ease virus (MDV), is a lymphoproliferative disease of
chickens that causes significant economic losses in the
poultry industry. MDV belongs to the genus Mardivirus
of the Alphaherpesvirinae subfamily, but it shares biolo-
gical characteristics with gammaherpesviruses, for exam-
ple its ability to induce T-cell lymphoma and its slow
growth in cell culture [1]. MDV replicates in B and T
lymphocytes during early cytolytic infection and subse-
quently establishes a latent infection of T lymphocytes
that are finally transformed, which leads to the develop-
ment of lymphomatous lesions in the visceral organs,
peripheral nerves and skin [2]. MD, therefore, serves as
an elegant model for understanding the molecular
mechanisms of herpesvirus-induced latency and onco-
genesis [3].
The MDV genome encodes at least 80 proteins [4],
among which Meq is considered to be the major onco-
protein [3]. Meq is a protein of 339 amino acids (aa)
that is expressed during both the cytolytic and the
latent/tumor phases of infection [5]. Over-expression of
Meq results in transformation of fibroblast cells [6-8].
Furthermore, analysis of a recombinant MDV mutant
virus that lacks the meq gene demonstrated that Meq is
required for transformation of T lymphocytes [9].
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any medium, provided the original work is properly cited.Figure 1 Interaction between Meq and p53. (A) Schematic representation of the wild-type Meq protein (Meq) and the Meq protein of the
deletion mutant (Meq-Δp53BD), which lacked the p53 binding region. The numbers indicate amino acid positions. (B) Yeast AH109 cells were
transformed with a combination of the indicated plasmids and selected on low-stringency and high-stringency media. (C) CEF cells were
transfected with a combination of the indicated plasmids and incubated for 24 h. Flag-tagged influenza virus M1 protein (Flag-M1) was used as
a negative control. The cell lysates prepared from the transfectants were subjected to immunoprecipitation using anti-Flag antibodies. The
immunoprecipitates were immunoblotted with anti-GFP antibodies. The cell lysates were included as a loading control. IP, immunoprecipitation.
WB, Western blot. (D) CEF cells were co-transfected with Flag-Meq and GFP-p53 and incubated for 24 h. The transfectants were fixed in a 1:1
solution of methanol/acetone for 20 min at -20°C and immunostained with anti-Flag antibodies (panel a, red). The cells were also stained for
DNA with 4’,6’-diamidino-2-phenylindole (DAPI) (panel d, blue). Panel c shows the merged images of panels a and b (green). Bar, 5 μm.
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Page 2 of 11Structurally, Meq contains a DNA-binding domain, a
basic region-leucine zipper (bZIP) domain that is similar
to that of members of the Jun/Fos family of transcrip-
tional activators [10], and a proline-rich transactivation
domain at the carboxy terminus [11] (Figure 1A). Like
other bZIP proteins, Meq forms homodimers with itself,
and heterodimers with cellular proteins that include
J u n B ,c - J u n ,c - F o s ,S N F ,A T F ,C R E Ba n dC / E B Pt o
transactivate its target genes [3]. In addition, Meq inter-
acts with non-bZIP cellular proteins, such as p53,
retinoblastoma protein, cyclin-dependent kinase 2,
C-terminal binding protein-1 and heat shock protein
70 [5,12-14]. Despite these observations, the molecular
mechanisms of transformation induced by Meq are still
not understood completely.
The tumor suppressor protein p53 plays a major role
in the protection of cells from malignant transformation
via its ability to transactivate target gene expression and
mediate downstream events, such as apoptosis and cell
cycle arrest [15]. Inhibition of p53-mediated transcrip-
tional activity by viral oncoproteins contributes to virus-
mediated oncogenesis. The main mechanism involved is
the binding of viral proteins to p53, which reduces its
transcriptional activity [16]. For example, SV40 T anti-
gen, adenovirus E1B55K, and HBx from hepatitis B
virus bind directly to p53 and inhibit p53-mediated
transcriptional activity [17-19]. In the Herpesviridae
family, the immediate-early protein BZLF1 and the
latency protein EBNA3C of Epstein-Barr virus, a gam-
maherpesvirus that shares biological characteristics with
MDV, have been shown to form a complex with p53
and to disrupt p53-mediated transcriptional activity
[20,21]. Given the nature of p53 as a common target for
several viral oncoproteins, it is reasonable to speculate
that p53 may be a target of the Meq oncoprotein of
MDV.
It has been shown previously that p53 has a similar
distribution to Meq in MD tumor cells [22], and that
M e qi sa b l et ob i n dp 5 3in vitro as demonstrated using
a protein-binding assay [12]. These observations
prompted us to examine whether the interaction
between Meq and p53 occurs in cells, and to investigate
the biological significance of this interaction. We found
that Meq binds directly to p53 and that this interaction
resulted in inhibition of the transcriptional and apopto-
tic activities of p53.
Results
Meq binds directly to p53
The Meq protein has been shown to interact with p53
in vitro in a protein-binding assay, and the p53 binding
region resides between aa residues 54 and 127 [12] (Fig-
ure 1A). To test whether this interaction occurs in cells,
we employed a yeast two-hybrid assay. Recombinant
plasmids pGBKT7-Meq (wild-type Meq) or pGBKT7-
Meq-Δp53BD (a Meq deletion mutant that lacks the
p53 binding region), expressing the bait fusion protein,
were co-transformed with recombinant plasmid
pGADT7-p53 (chicken p53), expressing the prey fusion
protein, into yeast AH109 cells and selected on low-
stringency and high-stringency media. The yeast cells
co-transformed with the vectors pGBKT7-Meq and
pGADT7 did not grow on high-stringency medium
(Figure 1B, section 1), which suggests that Meq did not
activate reporter genes autonomously. However, when
pGBKT7-Meq was co-transformed with pGADT7-p53,
the yeast cells grew on high-stringency medium (Figure
1B, section 2), which suggests that Meq interacted with
p53. The yeast cells co-transformed with pGBKT7-Meq-
Δp53BD and pGADT7-p53 did not grow on high-
stringency medium (Figure 1B, section 4), confirming
that the region of the Meq protein that spans aa resi-
dues 54 to 127 is required for the interaction with p53.
To determine whether the interaction between Meq
and p53 occurs in host cells naturally permissive for
MDV, primary chick embryo fibroblasts (CEFs) were co-
transfected with Flag-tagged chicken p53 (Flag-p53) and
GFP-tagged Meq (GFP-Meq) or GFP-tagged Meq-
Δp53BD (GFP-Meq-Δp53BD) and analyzed by an
immunoprecipitation assay. The Flag-tagged influenza
virus M1 protein (Flag-M1) was used as a negative con-
trol. CEFs were used in this assay for the following rea-
sons: (i) they are naturally permissive for MDV
replication, and (ii) they can be transformed by MDV
[6]. Flag-p53 immunoprecipitated GFP-Meq, but not
GFP-Meq-Δp53BD (Figure 1C), which confirms that the
interaction between Meq and p53 occurs in host cells
that are naturally permissive for MDV.
It has been reported previously that the subcellular
localization of p53 is similar to that of Meq in MD
tumor cells [22]. Given that there is no commercial anti-
body suitable for the detection of chicken p53, we visua-
lized the subcellular localization of Meq and p53 in
CEFs that were co-transfected transiently with GFP-p53
and Flag-tagged Meq (Flag-Meq). The Flag-Meq protein
was expressed in the nucleus (Figure 1D, panel a), as
reported previously [23]. The co-localization of Flag-
Meq and GFP-p53 was observed in CEFs (Figure 1D,
panel c), and also in other types of cells, such as H1299,
DF-1 and Vero cells (data not shown).
Meq inhibits the transcriptional activity of p53
The transcriptional activity of p53 is important for p53-
mediated regulation [15], and most viral proteins that
interact with p53 have been reported to suppress p53
t r a n s c r i p t i o n a la c t i v i t y[ 1 6 ] .T h e r e f o r e ,t oi n v e s t i g a t e
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Page 3 of 11whether the interaction between Meq and p53 influ-
ences the transcriptional activity of p53, p53-null H1299
cells were co-transfected with Flag-p53 and Flag-Meq in
t h ep r e s e n c eo fac h i c k e np 5 3luciferase reporter plas-
mid (p53-Luc) that contains four tandem repeats of the
chicken p53 consensus binding site [24]. The luciferase
activity was measured 24 h post-transfection. The
expression of Flag-Meq and Flag-p53 in the transfectants
was confirmed by western blot analysis (Figure 2A).
Expression of Flag-p53 alone (Flag-p53+Flag-Vec)
Figure 2 Meq inhibits the transcriptional activity of p53. (A and B) H1299 cells were co-transfected transiently with a combination of the
indicated plasmids in the presence of the p53 luciferase reporter plasmid (p53-Luc). The expression of the indicated plasmids was detected by
western blot analysis (A). The luciferase activity of the transfectants was measured 24 h post-transfection (B). *p < 0.05 compared with cells
transfected with Flag-p53 alone (Flag-p53+Flag-Vec). (C) H1299 cells were transfected transiently with increasing amounts of Flag-Meq in the
presence of Flag-p53 and p53-Luc. The expression of Flag-Meq and Flag-p53 was detected by western blot analysis. *p < 0.05 compared with
cells transfected with Flag-p53 alone (Flag-p53+Flag-Vec). (D and E) CEF cells were transfected transiently with the indicated plasmids in the
presence of p21 promoter luciferase reporter plasmids (D) or MDM2 promoter luciferase reporter plasmids (E). *p < 0.05 compared with cells
transfected with Flag-vector (Flag-Vec).
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Page 4 of 11resulted in a significant enhancement of luciferase activity
when compared with the Flag-vector (Flag-Vec+Flag-
Vec), but the enhanced luciferase activity was reduced
significantly by co-expression of Flag-Meq (Flag-p53
+Flag-Meq) (Figure 2B). Next, H1299 cells were co-trans-
fected with Flag-p53 and increasing amounts of Flag-Meq
in the presence of p53-Luc. The expression of Flag-Meq
and Flag-p53 was detected by western blot analysis. The
luciferase activity of the transfectants decreased gradually
with increasing expression of Flag-Meq in a dose-depen-
dent manner (Figure 2C). These results suggested that
Meq inhibited the transcriptional activity of p53.
To assess the inhibitory effect of Meq on the tran-
scriptional activity of p53 further, we analyzed the influ-
ence of Meq on the expression of the p53 targeting
genes p21 [25] and MDM2 [26] in CEFs using a lucifer-
ase assay. A p21 promoter luciferase reporter plasmid
(p21-Luc) and an MDM2 promoter luciferase reporter
plasmid, both containing p53 response elements, were
co-transfected separately with Flag-Meq into CEFs, and
the luciferase activities were measured 24 h post-trans-
fection. As shown in Figure 2D and 2E, Meq reduced
the luciferase activity of both p21-Luc and MDM2-Luc
significantly, when compared with the Flag-vector (Flag-
Vec). Taken together, these observations suggested that
Meq inhibits p53-mediated transcriptional activity.
p53-mediated apoptosis is suppressed by Meq expression
To explore the functional significance of the interaction
between Meq and p53, we determined whether Meq
affects p53-mediated apoptosis, an active physiological
response that eliminates mutated or preneoplastic cells.
Flag-Meq was co-transfected with Flag-p53 into CEFs,
and apoptosis of the transfectants was analyzed using a
TUNEL assay. The expression of Flag-p53 and Flag-Meq
in the transfectants was confirmed by western blot ana-
lysis (data not shown). As shown in Figure 3, apoptosis
was detected in approximately 46% of cells transfected
with Flag-p53 alone (Flag-p53+Flag-Vec), which was sig-
nificantly higher than the percentage of apoptotic cells
among those transfected with the Flag-vector (Flag-Vec
+Flag-Vec). This suggests that Flag-p53 was able to
induce apoptosis in CEFs. However, in the presence of
Flag-Meq, p53-mediated apoptosis was reduced dramati-
cally, and was observed in only 12% of cells (Flag-p53
+Flag-Meq). These data revealed that Meq inhibited
p53-mediated apoptosis.
Meq inhibits p53 transcriptional activity, dependent on
physical interaction
A number of tumor virus proteins, such as SV40 T anti-
gen, E1B55K and HBx, disrupt the function of p53, and
this inhibition is dependent on the physical interaction
between these proteins [17-19]. We explored, therefore,
whether the inhibitory effect of Meq on p53 transcrip-
tion was dependent on their physical interaction. Flag-
p53 was co-transfected with Flag-Meq or Flag-Meq-
Δp53BD into H1299 cells in the presence of p53-Luc.
The deletion mutant of Meq-Δp53BD was unable to
bind p53, as shown in Figure 1. The inhibitory effects of
Flag-Meq and Flag-Meq-Δp53BD on the luciferase activ-
ity of p53-Luc were compared subsequently. The
expression of Flag-Meq reduced the luciferase activity
significantly; however, in contrast, no inhibitory effect
on luciferase activity was observed in the cells trans-
fected with Flag-Meq-Δp53BD (Figure 2A and 2B).
Similar results were observed in experiments that com-
pared the inhibitory effects of Flag-Meq and Flag-Meq-
Δp53BD on the luciferase activities of p21-luc and
MDM2-Luc (Figure 2D and 2E). Next, we compared the
inhibitory effects of Flag-Meq and Flag-Meq-Δp53BD
on apoptosis mediated by p53. As expected, Flag-Meq-
Δp53BD did not inhibit p53-mediated apoptosis (Figure
3). Taken together, these data suggested that Meq inhi-
bits p53 transcription and that this inhibition is depen-
dent on the physical interaction between Meq and p53.
Effects of Meq variants on p53 transcriptional activity
Meq is a polymorphic protein and several variants have
been characterized, including L-Meq (which contains an
insertion of 60 aa between residues190 and 191), S-Meq
(which contains a deletion of 41 aa between residues
190 and 191), VS-Meq (which contains a deletion of 92
aa between residues 174 and 175), and ΔMeq (com-
p o s e do f9 8a af r o mt h eN - t e r m i n a lr e g i o no fM e qa n d
a frame-shifted distinct C-terminus of 30 aa) [27-29]
(Figure 4A). Meq and its variants are expressed in MD
tumor cells and in MDV-infected cells, but their roles in
cytolytic infection and the establishment of latency or
transformation have not been elucidated fully. We
constructed recombinant plasmids that expressed
Flag-tagged Meq variants and confirmed their expres-
sion in transfected cells by western blot analysis (Fig-
ure 4B). To investigate the effects of the Meq variants
on p53 transcriptional activity, we co-transfected each
Meq variant with Flag-p53 into H1299 cells and ana-
lyzed p53 transcriptional activity using a luciferase
assay. As shown in Figure 5A, L-Meq and S-Meq
inhibited p53 transcriptional activity significantly, with
a similar efficiency to Meq, while ΔM e qs h o w e dn o
detectable inhibitory effect on transcription of p53.
Interestingly, VS-Meq, which contains the p53 binding
region but lacks a 92-aa region of the transactivation
domain, showed no inhibitory effect on p53 transcrip-
tional activity.
It has been reported previously that L-Meq and ΔMeq
are negative regulators of Meq, and suppress the trans-
activational activities of Meq [28,29]. It was therefore of
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the p53-inhibitory activity of Meq. Flag-Meq was co-
transfected with increasing amounts of each Meq variant
into H1299 cells in the presence of Flag-p53 and
p53-Luc, and the luciferase activities were measured 24
hp o s t - t r a n s f e c t i o n .L - M e qa n dS - M e qs h o w e dn o
enhanced or suppressive effect, while VS-Meq showed a
slight, but not significant, inhibitory effect on the p53-
inhibitory activity of Meq (data not shown). In contrast,
the inhibitory effect of Meq on the transcriptional activ-
ity of p53 was attenuated significantly by co-expression
of ΔMeq, in a dose-dependent manner (Figure 5B),
which suggests that ΔMeq is a negative regulator of
Meq. Taken together, these data suggested that the var-
iants of Meq have different effects on the transcriptional
activity of p53, and may play different roles during cyto-
lytic infection and the establishment of latency or
transformation.
Figure 3 Meq inhibits p53-mediated apoptosis. Flag-p53 was co-transfected into CEFs with Flag-Meq or Flag-Meq-Δp53BD at a 1:10 molar
ratio. (A) Apoptotic cells (red) were stained with a TUNEL assay kit. The cells were also stained for DNA with DAPI (blue). (B) The percentage of
apoptotic cells (red) was determined and is shown on the graph as the average ± standard error from three experiments. More than 500 cells
were examined for each experiment. *p < 0.05 compared with cells transfected with Flag-p53 alone (Flag-p53+Flag-Vec).
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Herpesviruses are important pathogens that are asso-
ciated with a wide range of diseases in humans and
other animals. MDV is one of the most contagious and
highly oncogenic herpesviruses, and MD is the only
neoplastic disease for which an effective vaccine has
been employed widely [3]. However, with increasing
reports of vaccination breaks and the emergence of
more virulent pathotypes, MD continues to pose a
severe threat to the poultry industry, and the develop-
ment of more effective control strategies remains a sig-
nificant challenge [4]. Therefore, a fundamental
understanding of the molecular mechanisms of MD
oncogenesis is important, not only for the development
of more sustainable control strategies, but also to
increase understanding of some of the principles of
virus-induced lymphomagenesis.
The tumor suppressor protein p53 plays a major role
in the protection of cells from malignant transformation
and has been targeted by numerous viral oncoproteins
[16]. A preliminary study reported that Meq binds to
p53 in vitro, as determined by a protein-binding assay
[12]. In this study, we used a yeast two-hybrid assay to
show that Meq interacts directly with p53 (Figure 1B).
We also demonstrated the interaction between Meq and
p53 in host cells naturally permissive for MDV (Figure
1C), which confirmed further the interaction between
these two proteins. Given that the tumor suppressor
function of p53 is linked closely to its ability to transac-
tivate target gene expression and mediate downstream
events [15], we investigated the biological significance of
the interaction between Meq and p53 on p53-mediated
transcriptional activities. Exogenous expression of Meq
resulted in inhibition of p53-mediated transcriptional
Figure 4 Construction of Meq variants. (A) Schematic representation of Meq variants (L-Meq, S-Meq, VS-Meq and ΔMeq). The numbers
indicate amino acid positions (please refer to Fig. 1A for the protein structure of Meq). (B) H1299 cells were transfected transiently with each
Flag-tagged Meq variant and the expression was determined by western blot analysis 24 h post-transfection.
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that p53 is targeted by the Meq oncoprotein of MDV.
Although the mechanisms of the abrogation of p53
transcriptional activity in virus-induced oncogenesis are
not understood fully, the main mechanism employed by
oncoviruses involves the direct binding of viral proteins
to p53. This results in modulation of the functions of
p53, mainly via acceleration of its degradation, seques-
tration of p53 in the cytoplasm, blockage of the DNA-
binding capacity of p53, and/or blockage of the interac-
tion of p53 with transcription coactivators [16]. We
found that Meq-Δp53BD, the Meq deletion mutant that
lacks the p53 binding region and is unable to bind p53
(Figure 1), did not inhibit p53-mediated transcriptional
activity and apoptosis (Figures 2 and 3). This suggests
that the inhibitory effect of Meq on the transcription of
p53 is dependent on the physical interaction of these
two proteins. However, this interaction between Meq
and p53 did not affect the stability of the protein or the
subcellular localization of p53 (data not shown). The
mechanism that underlies the p53-inhibitory effect of
Meq is a current topic of investigation in our laboratory.
Figure 5 Analysis of the effect of the Meq variants on p53 transcriptional activity. (A) H1299 cells were co-transfected transiently with a
combination of the indicated plasmids in the presence of the p53 luciferase reporter plasmid. *p < 0.05 compared with cells transfected with
Flag-p53 alone (Flag-p53+Flag-Vec). (B) H1299 cells were co-transfected transiently with a combination of the indicated plasmids in the presence
of p53 luciferase reporter plasmid. *p < 0.05 compared with cells transfected with Flag-Meq alone.
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Meq and ΔMeq (Figure 4A), have been characterized in
MD tumor cells and MDV-infected cells [27-29], but
their functions during cytolytic infection and the estab-
lishment of latency or transformation have not been elu-
cidated fully. In the context of the inhibition of the
function of p53, L-Meq and S-Meq were found to inhi-
bit p53 transcriptional activity with a similar efficiency
to Meq (Figure 5A). This implies that L-Meq and S-
Meq may also play a role in cellular transformation, in a
similar way to the Meq protein. Interestingly, VS-Meq,
which contains the p53-binding region but lacks a 92-aa
region located in the transactivation domain, showed no
inhibitory effect on the transcriptional activity of p53
(Figure 5A), which suggests that Meq requires additional
region(s) to exert this inhibitory function cooperatively.
Although ΔMeq did not show a significant inhibitory
effect on the transcriptional activity of p53, it sup-
pressed the p53-inhibitory activity of Meq significantly
(Figure 5B), which suggests that it acts as a negative reg-
ulator of Meq, as demonstrated in a previous study [29].
These data also suggested that Meq proteins play com-
plex roles during cytolytic infection and the establish-
ment of latency or transformation.
Conclusions
In conclusion, we confirmed that Meq interacted
directly with p53. Exogenous expression of Meq resulted
in the inhibition of p53-mediated transcriptional activity
and apoptosis. The inhibitory effect of Meq on p53-
mediated transcriptional activity was dependent on the
physical interaction between these two proteins. The
M e qv a r i a n t sL - M e qa n dS - M e q ,b u tn o tV S - M e qa n d
ΔMeq, exerted inhibitory effects on the transcriptional
activity of p53. In addition, ΔMeq was found to work as
a negative regulator of Meq. Our findings provide valu-
able insight into the molecular basis of the function of
Meq in the oncogenesis of MDV.
Methods
Cells, viruses and antibodies
The CEFs were prepared from nine-day-old embryo-
nated specific-pathogen-free chicken eggs and cultured
using standard techniques. The human non-small lung
cancer cell line H1299 (p53-null) and the MD tumor
cell line MSB-1 were maintained in Dulbecco’s modified
Eagle’s medium and RPMI 1640 medium, respectively,
supplemented with 10% fetal bovine serum, in an atmo-
sphere containing 5% CO2. A very virulent strain of
MDV, strain RB1B, was propagated on CEFs. The com-
mercial antibodies used were an anti-Flag monoclonal
a n t i b o d y( M 2 ,S i g m a ,S t .L o u i s ,M O ,U S A ) ,ar a b b i t
anti-Flag polyclonal antibody (Sigma), an anti-GFP
monoclonal antibody (ab1218, Abcam, Cambridge, MA,
USA), an anti-b-actin monoclonal antibody (AC-15,
Sigma), a horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG antibody (sc-2004, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), a HRP-conjugated goat
anti-mouse IgG antibody (sc-2005, Santa Cruz) and an
Alexa Fluor 594-conjugated goat anti-mouse IgG (H+L)
2 monoclonal antibody (Molecular Probes, Eugene, OR,
USA).
Construction of expression plasmids and transient
transfection
The full-length DNA fragment encoding the wild-type
Meq protein was amplified by PCR from the RB1B
MDV strain and subcloned into the expression vectors
p3xFLAG-CMV-7.1 and pEGFP-C1, to generate the
recombinant plasmids Flag-Meq and GFP-Meq, respec-
tively. The L-Meq variant was amplified by PCR from
MSB-1 cells and subcloned into the expression vector
p3xFLAG-CMV-7.1. The Meq deletion mutant (Meq-
Δp53BD) that lacked the p53 binding domain (Figure
1A), and several variants of Meq including S-Meq, VS-
Meq and ΔMeq (Figure 4A), were generated by PCR-
based site-directed mutagenesis [30] using Flag-Meq as
the template. The primers used are shown in Table 1.
Chicken p53 cDNA [31], a gift provided generously by
Dr. Thierry Soussi from Université Pierre et Marie
Curie-Paris, France, was subcloned into the expression
vectors p3xFLAG-CMV-7.1 and pEGFP-C1 to generate
the recombinant plasmids Flag-p53 and GFP-p53,
respectively. The cells were plated onto tissue culture
plates 24 h before transfection. Transfection was per-
formed using the Lipofectamine2000 transfection
reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions.
Luciferase assay
Cells were transfected with the indicated expression
plasmids in the presence of the luciferase reporter
Table 1 primer sequence
Gene name Primer sequence (5’ to 3’)
Meq GCGAATTCTATGTCTCAGGAGCCAGAGCC
TTATCTCGAGTCAGGGTCTCCCGTCACC
Meq-Δp53BD CCTTCCCTGACGGCCTATCTGTACCCCTAACGGTGACCCT
AGGGTCACCGTTAGGGGTACAGATAGGCCGTCAGGGAAGG
L-Meq GCGAATTCTATGTCTCAGGAGCCAGAGCC
GGCTCGAGTTATGAGGGCGCAAACTT
S-Meq GCGCCCAGCTCTGCTCGACCCCACCACCTCCCATCTGTAC
GTACAGATGGGAGGTGGTGGGGTCGAGCAGAGCTGGGCGC
VS-Meq CCCAACCTCCTATCTGTACCCCTCCATCGCCGGGGACGGT
ACCGTCCCCGGCGATGGAGGGGTACAGATAGGAGGTTGGG
ΔMeq GCTGCAGAGGGCCAATGAACACCGAGGATCCCGAACAGGA
TCCTGTTCGGGATCCTCGGTGTTCATTGGCCCTCTGCAGC
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T K( P r o m e g a ,M a d i s o n ,W I ,U S A ) .T h ec h i c k e np 5 3
luciferase reporter plasmid (p53-Luc) was provided gen-
erously by Dr. Byung-Whi Kong from the University of
Arkansas, USA [24]. The p21 luciferase reporter plasmid
(p21-Luc) and MDM2 luciferase reporter plasmid
(MDM2-Luc) were gifts from Dr. Kenji Fukasawa (H.
Lee Moffitt Cancer Center & Research Institute, USA).
Transfectants were harvested 24 h post-transfection and
luciferase assays were carried out with the Dual-lucifer-
ase reporter assay system (Promega), according to the
manufacturer’s protocol. The firefly luciferase activity of
individual cell lysates was normalized to Renilla lucifer-
ase activity. All assays were performed at least in
triplicate.
TUNEL assay
CEFs grown on coverslips were co-transfected transi-
ently with Flag-p53 and Flag-Meq or Flag-Meq-Δp53BD
at a molar ratio of 1:10 and incubated for 24 h.
The transfectants were fixed with 4% paraformalde-
hyde, stained using the In Situ Cell Death Detection Kit,
TMR red (Roche, Mannheim, Germany), and examined
under a fluorescence microscope.
Yeast two-hybrid assay
The yeast two-hybrid assay was carried out using the
MATCHMAKER GAL4 two-hybrid system 3 (Clontech,
Palo Alto, CA, USA), and all procedures were performed
according to the manufacturer’s protocols. Meq and
Meq-Δp53BD were subcloned in-frame with the GAL4
DNA binding domain into the pGBKT7 vector to gener-
ate the bait plasmids pGBKT7-Meq and pGBKT7-Meq-
Δp53BD, respectively. Cells of the yeast host strain
AH109 were transformed with pGBKT7-Meq or
pGBKT7-Meq-Δp53BD to confirm that they did not
activate reporter genes autonomously. Chicken p53 was
subcloned in-frame with the GAL4 activation domain
into the pGADT7 vector to generate the prey plasmid
pGADT7-p53. To investigate the interaction between
p53 and Meq, pGADT7-p53 was co-transformed with
pGBKT7-Meq or pGBKT7-Meq-Δp53BD into yeast
AH109 cells. The transformants were selected on low-
stringency medium plates lacking tryptophan and leu-
cine, and on high-stringency medium plates lacking
tryptophan, leucine, histidine and adenine. The positive
clones were confirmed by PCR analysis.
Western blot analysis, immunofluorescence and
immunoprecipitation assays
Western blot analysis, immunofluorescence and immu-
noprecipitation assays were performed as described
previously [32].
Statistics
All measured values are expressed as the mean ± SE.
The significance of the results was analyzed using Stu-
dent’s t-test, and p values less than 0.05 were considered
significant.
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